Marcus Butler, University of Toronto

Research

Breast Cancer Colitis Gut Microbiome Head And Neck Cancers Immune Checkpoint Inhibitors Immunotherapy Melanoma Solid Tumors

Latest papers

Body Composition and Melanoma Outcomes in Patients on Immunotherapy or Targeted Therapy: An Analysis from Canadian Melanoma Research Network.
Current oncology (Toronto, Ont.) · 2026
Characteristics and Outcomes of Patients with Early or Late Uveal Melanoma Metastasis: A Review.
Ocular oncology and pathology · 2026
Beyond the Hazard Ratio: Rethinking Survival Reporting in Cardio-Oncology With Restricted Mean Survival Time.
JACC. CardioOncology · 2026 · senior author

All 27 publications

Latest funding

Spatial Dynamics of Interferon Signaling within the Tumor Microenvironment
CIHR · 2025 · Co-investigator
$1,197,226
Fecal microbiota transplantation in combination with immune checkpoint blockade in patients with advanced melanoma: A randomized phase II trial
CIHR · 2023 · Co-investigator
$1,786,273
Epigenetic Drivers in Metastatic Melanoma and Chromatin Loop-Specific Targeting Strategies
CIHR · 2023 · Co-investigator
$784,126

All 7 grants and awards

27 publications.

01

Body Composition and Melanoma Outcomes in Patients on Immunotherapy or Targeted Therapy: An Analysis from Canadian Melanoma Research Network.

Biglari M, Ali S, Muniz T, Butler M, Ennis M, Ernst S, Lohmann AE

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33070403 PMID: 42505205

02

Characteristics and Outcomes of Patients with Early or Late Uveal Melanoma Metastasis: A Review.

Lin KL, Lim LA, Sacco JJ, Butler M, Carvajal R, Gwadry-Sridhar F, Joshua A

Ocular oncology and pathology2026

DOI: 10.1159/000552152 PMID: 42403974

03

Beyond the Hazard Ratio: Rethinking Survival Reporting in Cardio-Oncology With Restricted Mean Survival Time.

Maselli-Schoueri JH, Saibil SD, Gabriel da Silva Negrini V, Neto AS, Butler M

JACC. CardioOncology2026Senior author

DOI: 10.1016/j.jaccao.2025.11.003 PMID: 41705758

04

Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.

Rose AAN, Maxwell J, Rousselle E, Mukonoweshuro CL, Elkholi IE, Riaud M, Biondini M, Cianfarano E, Soria-Bretones I, Tobin C, McGuire M, Law RWY, Elia AJ, Wang BX, King I, Zhang T, Pugh TJ, Kamil ZS, Butler M, Shepherd FA, Leighl NB, Razak AA, Hansen A, Saibil SD, Bedard PL, Siegel PM, Siu LL, Cescon DW, Spreafico A

Nature communications2026

DOI: 10.1038/s41467-025-68076-7 PMID: 41484121

05

Massive Solitary Liver Metastasis From a Locally Recurrent Basal Cell Carcinoma Treated With Stereotactic Body Radiation Therapy: A Rare Manifestation of a Common Disease.

Gerard IJ, Butler M, Martinez EA, Sauder M, Kim TK, Faye MD, Glynn AM, Kamil ZS, Dawson LA

Advances in radiation oncology2026

DOI: 10.1016/j.adro.2026.102035 PMID: 42306309

06

Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial.

Park JC, Curti B, Butler M, Wehrenberg-Klee E, Elassal J, Tighe R, Battula S, Iodice G, Kaufman HL, Kirkwood JM

Nature communications2025

DOI: 10.1038/s41467-025-63579-9 PMID: 41022754

07

Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.

Shen Q, Murakami K, Sotov V, Butler M, Ohashi PS, Reedijk M

Science advances2024

DOI: 10.1126/sciadv.ado8275 PMID: 39475614

08

Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy.

Zheng W, Marini W, Murakami K, Sotov V, Butler M, Gorrini C, Ohashi PS, Reedijk M

Nature communications2024

DOI: 10.1038/s41467-024-52553-6 PMID: 39353903

09

Checkpoint inhibitor hepatotoxicity: pathogenesis and management.

Cunningham M, Gupta R, Butler M

Hepatology (Baltimore, Md.)2024Senior author

DOI: 10.1097/hep.0000000000000045 PMID: 36633259

10

Promoting Self-management and Patient Activation Through eHealth: Protocol for a Systematic Literature Review and Meta-analysis.

Moradian S, Maguire R, Liu G, Krzyzanowska MK, Butler M, Cheung C, Signorile M, Gregorio N, Ghasemi S, Howell D

JMIR research protocols2023

DOI: 10.2196/38758 PMID: 36862481

Spatial Dynamics of Interferon Signaling within the Tumor Microenvironment

Co-investigatorCIHR2025Project Grant

Principal investigators: Brooks, David; Campbell, Kieran R

Keywords: Cancer; Immune Cells; Immunotherapy; Interferon; Spatial Analysis

$1,197,226

Fecal microbiota transplantation in combination with immune checkpoint blockade in patients with advanced melanoma: A randomized phase II trial

Co-investigatorCIHR2023Project Grant

Principal investigators: Dancey, Janet E; Elkrief, Arielle; Lenehan, John; Maleki, Saman; Routy, Bertrand; Silverman, Michael

Keywords: Fecal Microbiota Transplant; Melanoma; Microbiome; Multicentre; Phase Ii; Progression-Free Survival; Randomized Controlled Trial

$1,786,273

Epigenetic Drivers in Metastatic Melanoma and Chromatin Loop-Specific Targeting Strategies

Co-investigatorCIHR2023Project Grant

Principal investigators: Orouji, Elias

Keywords: Chromatin Architecture; Epigenomics; Melanoma; Metastasis

$784,126

Mechanisms of IRF2-driven immune regulation in the tumor microenvironment

Co-investigatorCIHR2022Project Grant

Principal investigators: Brooks, David

Keywords: Cd8 T Cells; Immunotherapy; Interferon; Irf2; T Cell Exhaustion; Tumor Immunology

$1,118,814

A multi institutional study evaluating the role of the gut microbiome on immune checkpoint inhibitor efficacy and toxicity in advanced solid tumors

Principal investigatorCIHR2018Team Grant: Canadian Microbiome Initiative 2: Research Teams - LOI

Principal investigators: Martin, Alberto; Butler, Marcus O; Pezo, Rossanna C; Siu, Lillian

Keywords: Breast Cancer; Colitis; Gut Microbiome; Head And Neck Cancers; Immune Checkpoint Inhibitors; Immunotherapy; Melanoma; Solid Tumors

$25,000

Immune Regulation during Chronic Disease

Co-investigatorCIHR2015Foundation Grant

Principal investigators: Brooks, David

Keywords: Chronic Inflammation; Co-Infection And Cancer; Immune Regulation; Immunosuppression; Immunotherapy; Inhibitory Molecules; Interferon; Lymphocytic Choriomeningitis Virus; T Cell Exhaustion; Viral Persistence

$5,081,508

Regulating CD8 immunity and tumor immunity

Co-investigatorCIHR2014Foundation Grant

Principal investigators: Ohashi, Pamela S

Keywords: Coinhibitory Molecules; Costimulatory Molecules; Cytotoxic T Cells; Immunotherapy; Nk Cells; T Cell Lineages; Tumor Infiltrating Lymphocytes; Tumor Microenvironment

$2,807,333

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Oncology
Immunology
Rehabilitation Science
Surgery and Cancer
Psychosocial Oncology and Palliative Care
Department of Surgery
Radiation Oncology
Other

Applying for

Paper to mention

Subject: Prospective PhD student: Breast Cancer Dear Professor Butler, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Body Composition and Melanoma Outcomes in Patients on Immunotherapy or Targeted Therapy: An Analysis from Canadian Melanoma Research Network." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]